BACKGROUND: The discovery of the c-KIT mutation and the advent of targeted drug therapy with imatinib mesylate have revolutionized the management of gastrointestinal stromal tumors (GISTs). The outcome of patients with surgically treated GISTs treated in the era of targeted drug therapy was assessed and factors associated with adverse outcomes determined. MATERIALS AND METHODS: Patients with GISTs requiring surgery at a tertiary care center from 2002 to 2007 were reviewed and prognostic factors determined. RESULTS: Forty patients were surgically treated for GISTs. The median age at presentation was 59 years. The stomach (55%) was the main site of primary disease. The median tumor size was 7 cm. Eleven (28%) patients had metastatic disease at presentation. Surgery was undertaken in all patients with curative intent. Multi-organ resection was required in 10 (25%) patients. Imatinib mesylate was administered postoperatively in 68% of cases. Median follow-up was 24 months. There was a 40% recurrence rate with 63% undergoing repeat surgical resection. The peritoneum and liver were the main sites of recurrent disease. The 5-year disease-specific survival and disease-free survival (DFS) were 65% and 35%, respectively. High mitotic rate (P = 0.017) and tumor size greater than 10 cm (P = 0.009) were the only prognostically significant adverse factors of DFS on multivariate analysis, independent of imatinib mesylate treatment. CONCLUSION: Aggressive surgical treatment and follow-up of GISTs, combined with targeted drug therapy, leads to long-term DFS survival. Tumor recurrence is independently associated with a high tumor mitotic rate and size greater than 10 cm, despite the use of adjuvant targeted drug therapy.
BACKGROUND: The discovery of the c-KIT mutation and the advent of targeted drug therapy with imatinib mesylate have revolutionized the management of gastrointestinal stromal tumors (GISTs). The outcome of patients with surgically treated GISTs treated in the era of targeted drug therapy was assessed and factors associated with adverse outcomes determined. MATERIALS AND METHODS:Patients with GISTs requiring surgery at a tertiary care center from 2002 to 2007 were reviewed and prognostic factors determined. RESULTS: Forty patients were surgically treated for GISTs. The median age at presentation was 59 years. The stomach (55%) was the main site of primary disease. The median tumor size was 7 cm. Eleven (28%) patients had metastatic disease at presentation. Surgery was undertaken in all patients with curative intent. Multi-organ resection was required in 10 (25%) patients. Imatinib mesylate was administered postoperatively in 68% of cases. Median follow-up was 24 months. There was a 40% recurrence rate with 63% undergoing repeat surgical resection. The peritoneum and liver were the main sites of recurrent disease. The 5-year disease-specific survival and disease-free survival (DFS) were 65% and 35%, respectively. High mitotic rate (P = 0.017) and tumor size greater than 10 cm (P = 0.009) were the only prognostically significant adverse factors of DFS on multivariate analysis, independent of imatinib mesylate treatment. CONCLUSION: Aggressive surgical treatment and follow-up of GISTs, combined with targeted drug therapy, leads to long-term DFS survival. Tumor recurrence is independently associated with a high tumor mitotic rate and size greater than 10 cm, despite the use of adjuvant targeted drug therapy.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: J A Crosby; C N Catton; A Davis; J Couture; B O'Sullivan; R Kandel; C J Swallow Journal: Ann Surg Oncol Date: 2001 Jan-Feb Impact factor: 5.344
Authors: Maria Debiec-Rychter; Jan Cools; Herlinde Dumez; Raf Sciot; Michel Stul; Nicole Mentens; Hilde Vranckx; Bartosz Wasag; Hans Prenen; Johannes Roesel; Anne Hagemeijer; Allan Van Oosterom; Peter Marynen Journal: Gastroenterology Date: 2005-02 Impact factor: 22.682
Authors: Imran Hassan; Y Nancy You; Roman Shyyan; Eric J Dozois; Thomas C Smyrk; Scott H Okuno; Cathy D Schleck; David O Hodge; John H Donohue Journal: Ann Surg Oncol Date: 2007-11-14 Impact factor: 5.344
Authors: B Nilsson; K Sjölund; L-G Kindblom; J M Meis-Kindblom; P Bümming; O Nilsson; J Andersson; H Ahlman Journal: Br J Cancer Date: 2007-05-29 Impact factor: 7.640
Authors: Ferdinando C M Cananzi; Bruno Lorenzi; Ajay Belgaumkar; Charlotte Benson; Ian Judson; Satvinder Mudan Journal: Langenbecks Arch Surg Date: 2014-01-12 Impact factor: 3.445
Authors: Mark B Ulanja; Mohit Rishi; Bryce D Beutler; Kenneth G Konam; Santhosh Ambika; Tomas Hinojosa; Francis T Djankpa; Wei Yang; Nageshwara Gullapalli Journal: J Racial Ethn Health Disparities Date: 2019-06-18
Authors: Isabelle Deshaies; Jovenel Cherenfant; Niraj J Gusani; Yixing Jiang; Harold A Harvey; Eric T Kimchi; Jussuf T Kaifi; Kevin F Staveley-O'Carroll Journal: Ther Clin Risk Manag Date: 2010-10-05 Impact factor: 2.423
Authors: Paolo G Sorelli; Patrizia Cohen; Bafour Amo-Takyi; Nikitas A Theodorou; Peter M Dawson Journal: World J Surg Oncol Date: 2011-04-27 Impact factor: 2.754